Premium
Thoracoscopic surgery for hepatocellular carcinoma located in the hepatic dome: Technical aspect and oncological results
Author(s) -
Yamao Takanobu,
Imai Katsunori,
Yamashita Yoichi,
Umezaki Naoki,
Tsukamoto Masayo,
Kitano Yuki,
Arima Kota,
Miyata Tatsunori,
Nakagawa Shigeki,
Okabe Hirohisa,
Nitta Hidetoshi,
Chikamoto Akira,
Ishiko Takatoshi,
Baba Hideo
Publication year - 2020
Publication title -
asian journal of endoscopic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.372
H-Index - 18
eISSN - 1758-5910
pISSN - 1758-5902
DOI - 10.1111/ases.12755
Subject(s) - medicine , hepatocellular carcinoma , radiofrequency ablation , surgery , diaphragmatic breathing , ablation , hepatectomy , thoracoscopy , complication , liver function , resection , alternative medicine , pathology
The objective of this study was to describe the surgical techniques for a thoracoscopic approach to treat hepatocellular carcinoma in the hepatic dome. Also, safety, feasibility, and long‐term outcomes were evaluated. Methods Surgical procedures were selected based on liver function, the extent and location of the tumor, and each patient's general condition. Thoracoscopic hepatic resection was performed under direct vision through a diaphragmatic incision. Thoracoscopic radiofrequency ablation (TRFA) was performed either with a transdiaphragmatic puncture for deeply located tumors or under direct vision through a diaphragmatic incision for subcapsular tumors. Results Thoracoscopic surgery was indicated for 107 patients with hepatocellular carcinoma in the hepatic dome. Among these patients, 5 underwent hepatectomy and 102 underwent radiofrequency ablation, which was more frequently employed in patients with impaired liver function. Of the patients who underwent radiofrequency ablation, 43 (42.2%) required a diaphragmatic incision. In the thoracoscopic hepatic resection group and TRFA group, the median operating time was 350 and 197 minutes, the median blood loss was 200 and 5 mL, and the complication rate was 12.7% and 20.0%, respectively. The 5‐year overall and disease‐free survival rates were 100% and 50.0% in the thoracoscopic hepatic resection group, respectively, and 60.7% and 18.1% in the TRFA group, respectively. Local recurrence after TRFA was observed in 10 patients (9.8%). Conclusion The thoracoscopic approach is safe and feasible, with promising short‐ and long‐term outcomes. It could serve as a treatment option for hepatocellular carcinoma in the hepatic dome.